Literature DB >> 21160143

Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy.

Mina Leyder1, Monika Laubach, Maria Breugelmans, Katelijn Keymolen, Jacques De Greve, Walter Foulon.   

Abstract

The treatment of pregnant women with chemotherapeutic drugs leads to congenital malformations in 10-20% of newborn children. We present a case of an ongoing 19-week-long pregnancy which was diagnosed in a 39-year-old woman who was being treated with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) chemotherapy for an infiltrating ductal carcinoma of the breast. After termination of the pregnancy, subsequent examination of the fetus revealed micrognathia and bilateral malformations of the hands and feet. The peak exposure of the fetus to the chemotherapeutic agents was in the 5th to 6th week of the pregnancy. Both the nature of the malformations and the timing of the administration of chemotherapy are similar to another case reported previously. We conclude that chemotherapy treatments with CEF in the 5th to 6th week of pregnancy specifically generate hand and foot abnormalities and micrognathia, which is consistent with an inhibition of proliferation, leading to cell death at this embryonic stage.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21160143     DOI: 10.1159/000317264

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  8 in total

Review 1.  Craniofacial malformations and their association with brain development: the importance of a multidisciplinary approach for treatment.

Authors:  Asher Ornoy
Journal:  Odontology       Date:  2019-06-06       Impact factor: 2.634

2.  Effect of chemotherapy exposure prior to pregnancy on fetal brain tissue and the potential protective role of quercetin.

Authors:  Z Doğan; S Kocahan; E Erdemli; E Köse; I Yılmaz; Z Ekincioğlu; N Ekinci; Y Turkoz
Journal:  Cytotechnology       Date:  2014-09-27       Impact factor: 2.058

Review 3.  Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.

Authors:  Silvia Triarico; Serena Rivetti; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 4.  Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.

Authors:  Loredana Colla; Davide Diena; Maura Rossetti; Ana Maria Manzione; Luca Marozio; Chiara Benedetto; Luigi Biancone
Journal:  J Nephrol       Date:  2018-02-23       Impact factor: 3.902

5.  Association of Chemotherapy Timing in Pregnancy With Congenital Malformation.

Authors:  Mathilde van Gerwen; Charlotte Maggen; Elyce Cardonick; Emma J Verwaaijen; Marry van den Heuvel-Eibrink; Roman G Shmakov; Ingrid Boere; Mina M Gziri; Petronella B Ottevanger; Christianne A R Lok; Michael Halaska; Long Ting Shao; Ilana Struys; Elisabeth M van Dijk-Lokkart; Kristel Van Calsteren; Robert Fruscio; Paolo Zola; Giovanna Scarfone; Frédéric Amant
Journal:  JAMA Netw Open       Date:  2021-06-01

Review 6.  Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.

Authors:  Marialuisa Framarino-dei-Malatesta; Giuseppina Perrone; Antonella Giancotti; Flavia Ventriglia; Martina Derme; Isabella Iannini; Valentina Tibaldi; Paola Galoppi; Paolo Sammartino; Gianluca Cascialli; Roberto Brunelli
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 7.  Cancer treatment in pregnant women.

Authors:  Pawel Basta; Anna Bak; Krzysztof Roszkowski
Journal:  Contemp Oncol (Pozn)       Date:  2014-10-18

Review 8.  Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?

Authors:  Marialuisa Framarino-Dei-Malatesta; Paolo Sammartino; Angela Napoli
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.